Discover 219 paid clinical trials in Des Moines, Iowa. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 219
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
for
Pancreatic Acinar Cell Carcinoma,
Location: Des Moines IA, Clive IA, West Des Moines IA, Ankeny IA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04858334
Phase 2, Recruiting
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
for
Metastatic Small Intestinal Adenocarcinoma,
Location: Des Moines IA, Clive IA, West Des Moines IA, Ankeny IA,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT04205968
Phase 2, Recruiting
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
for
Colorectal Cancer, Sarcopenia
Location: Des Moines IA, Clive IA, Ankeny IA, Fort Dodge IA,
Sponsor: Wake Forest University Health Sciences
Sex: All
Age: 60+
Code: NCT03998202
Recruiting
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
for
Castration Levels of Testosterone,
Location: Des Moines IA, Ames IA, Iowa City IA, Omaha NE,
Sponsor: SWOG Cancer Research Network
Sex: Male
Age: 18+
Code: NCT03678025
Phase 3, Recruiting
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
for
Brain Metastases
Location: Des Moines IA, Peoria IL, City of Saint Peters MO,
Sponsor: Canadian Cancer Trials Group
Sex: All
Age: 18+
Code: NCT03550391
Phase 3, Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors